PTO/ SB/26 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT

Docket Number (Optional)

5566

In re Application of: Aerts.

Application No. 10/595 584

Filed: May 23, 2006

For: Use of Deoxynojirimycin Derivative or a Pharmaceutical Salt Thereof

The owner*, Genzyme Corporation, of 100 percent interest in the instant application hereby disclaims, except as provided below. ion 73, so only ór

and as the term of said prior patent No. L granted on the instant application shall be enforce	ant granted on the instant application which would extend beyo JS7,528,153 as the term of said prior patent is defined in 35 U.S hortened by any terminal disclaimer. The owner hereby agrees the able only for and during such period that it and the prior patented on the instant application and is binding upon the grantee,	C. 154 and 1
application that would extend to the expiration da	not disclaim the terminal part of the term of any patent grants ate of the full statutory term as defined in 35 U.S.C. 154 and ently shortened by any terminal disclaimer," in the event that s	173 of the pr
expires for failure to pay a maintenance fee; is held unenforceable:		
is found invalid by a court of competent jurisdict is statutorily disclaimed in whole or terminally di has all claims canceled by a reexamination cert is reissued; or	isclaimed under 37 CFR 1.321:	
	on of its full statutory term as presently shortened by any termina	ıl disclaimer.
Check either box 1 or 2 below, if appropriate.		
For submissions on behalf of a business etc.), the undersigned is empowered to act	s/organization (e.g., corporation, partnership, university, govern ton behalf of the business/organization.	ment agency,
information and belief are believed to be true; and statements and the like so made are punishable b	e herein of my own knowledge are true and that all stateme further that these statements were made with the knowledge th y fine or imprisonment, or both, under Section 1001 of Title to any jeopardize the validity of the application or any patent issued	at willful false
2. The undersigned is an attorney of record.	Reg. No. 43.321	11/9/09
	Signature	Date
	Isabelle A. S. Blundell, Ph.D	**
Terminal disclaimer fee under 37 CFR 1.20(d)) is included.	
WARNING: Information on this for	rm may become public. Credit card information should n de credit card information and authorization on PTO-203	ot
	f terminal disclaimer is signed by the assignee (owner)	v .

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the minutes to complete, including gamening, preparing, and submitting the completed appreciation from to the USP-1U. Time was vary expending upon me inclinitivation case, Any comments on the amount of time you neque to complete this from and/or supposestors for reducing this building, should be sent to the Chief Information Officer, U.S. Patient and Trademant Office, U.S. Supartment of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FELS OR COMPLETED FORMST Or INS ADDRESS SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA22313-1450.